Webpackaging logo

B. Braun Medical Inc. uses needle-trap from Schreiner MediPharm for new pre-filled heparin syringe

  • Schreiner MediPharm
North America, USA, Europe, Germany, Austria, Germany, Health, Pharmaceuticals, Primary Packaging, Pharmaceutical Components, Syringes, Plastic, Laboratory, Testing, Certification, National Certifications, FDA Approved

Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions, has collaborated with B. Braun Medical Inc., located in Bethlehem, PA, who recently launched its prefilled syringe of Heparin Sodium Injection, USP utilizing Schreiner MediPharm’s label- integrated Needle-Trap system to the U.S. market.

According to B. Braun, this is the first prefilled heparin syringe with an integrated needle protection device approved by the U.S. Food and Drug Administration (FDA).

In the United States, syringes should be used with safety devices to protect healthcare staff against the risk of needlestick injuries. B. Braun Medical was looking for an efficient and safe needle protection solution for its prefilled Heparin Sodium Injection and found it in Needle-Trap from Schreiner MediPharm.

The Needle-Trap system is an internationally established solution that complies with the U.S. NIOSH requirements for safe instruments and has been awarded 510(k) Pre- Market Notification by the FDA for marketing in the United States.

“Clinical staff benefit from reliable protection against needlestick injuries because Needle-Trap’s activation is easy and irreversible. It is intuitive to use and requires no change in injection technique,” says Gene Dul, President of Schreiner MediPharm U.S.

Needle-Trap is the only label-based needle protection system on the market. The plastic needle trap is an integral component of the marking label and serves to secure the needle after the injection has been performed.

Due to its special construction, Needle- Trap can easily and cost-efficiently be integrated into existing pharmaceutical production processes. It requires only minor modifications of the application systems, no changes to secondary packaging, and minimal space during shipping, storage and disposal.

“Our products are designed to increase patient and clinician safety, while reducing medication errors and improving dosage accuracy and workflows. Obviously, efficient and economical manufacturing are equally important. Collaborating with Schreiner MediPharm allowed us to meet those needs,” says Leigh Nickens, Director of Marketing, Fluid Therapy and Injectable Drugs at B. Braun.

See also

Schreiner MediPharm and Applied DNA Sciences offer forensic counterfeit-proof feature for pharma labels

Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions, now offers a new forensic authentication feature for pharmaceutical labels in cooperation with Applied DNA Sciences. SigNature DNA is a high-security feature based on DNA markers with which pharmaceutical manufacturers can protect products against counterfeiting, and patients against potential health risks.

Schreiner MediPharm develops smart blister pack for clinical trial

Schreiner MediPharm has developed a smart blister pack for digital patient compliance monitoring to enhance medication adherence by clinical trial participants. Schreiner MediPharm implemented the smart packaging solution together with the Dutch technology company ECCT (Experts in Communications and Connectivity Technology). Employment of this electronic tool to manage and track processes during clinical trials marks a milestone for the pharmaceutical manufacturer.

Schreiner MediPharm supports Biotest AG with “Late Stage Customization” service for supply chain agility

Flexible production of functional labels successfully addresses market segmentation. Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions for over 65 years, recently implemented a special Late Stage Customization service in partnership with its customer, Biotest AG. The new process allows for faster production of functional labels on short demand. As a result, Biotest benefits from greater flexibility and is able to respond to market requirements with requisite agility, while Schreiner MediPharm assists its customer in meeting the demands of current segmentation trends in the pharmaceutical industry.

  • Brand Launch
  • English
  • Modified 30 Apr 2019
  • Hits 576